Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell activation is insufficient to drive SIV disease progression
Cristian Apetrei, … , Ruy M. Ribeiro, Ivona Pandrea
Cristian Apetrei, … , Ruy M. Ribeiro, Ivona Pandrea
Published July 24, 2023
Citation Information: JCI Insight. 2023;8(14):e161111. https://doi.org/10.1172/jci.insight.161111.
View: Text | PDF
Research Article AIDS/HIV Infectious disease

T cell activation is insufficient to drive SIV disease progression

  • Text
  • PDF
Abstract

Resolution of T cell activation and inflammation is a key determinant of the lack of SIV disease progression in African green monkeys (AGMs). Although frequently considered together, T cell activation occurs in response to viral stimulation of acquired immunity, while inflammation reflects innate immune responses to mucosal injury. We dissociated T cell activation from inflammation through regulatory T cell (Treg) depletion with Ontak (interleukin-2 coupled with diphtheria toxin) during early SIV infection of AGMs. This intervention abolished control of T cell immune activation beyond the transition from acute to chronic infection. Ontak had no effect on gut barrier integrity, microbial translocation, inflammation, and hypercoagulation, despite increasing T cell activation. Ontak administration increased macrophage counts yet decreased their activation. Persistent T cell activation influenced SIV pathogenesis, shifting the ramp-up in viral replication to earlier time points, prolonging the high levels of replication, and delaying CD4+ T cell restoration yet without any clinical or biological sign of disease progression in Treg-depleted AGMs. Thus, by inducing T cell activation without damaging mucosal barrier integrity, we showed that systemic T cell activation per se is not sufficient to drive disease progression, which suggests that control of systemic inflammation (likely through maintenance of gut integrity) is the key determinant of lack of disease progression in natural hosts of SIVs.

Authors

Cristian Apetrei, Thaidra Gaufin, Egidio Brocca-Cofano, Ranjit Sivanandham, Paola Sette, Tianyu He, Sindhuja Sivanandham, Natalie Martinez Sosa, Kathryn J. Martin, Kevin D. Raehtz, Adam J. Kleinman, Audrey Valentine, Noah Krampe, Rajeev Gautam, Andrew A. Lackner, Alan L. Landay, Ruy M. Ribeiro, Ivona Pandrea

×

Figure 7

Ontak administration to SIV-infected AGMs does not result in significant and persistent changes of the soluble biomarkers of systemic microbial translocation and gut integrity.

Options: View larger image (or click on image) Download as PowerPoint
Ontak administration to SIV-infected AGMs does not result in significant...
(A) No significant increase in the plasma LPS levels between Ontak-treated AGMs (n = 4, red) and controls (n = 4, gray). (B) No significant changes in the levels of sCD163, a marker of macrophage activation, between Ontak-treated AGMs (n = 4, red) and controls (n = 5, gray). (C) Testing the levels of I-FABP, a surrogate marker of mucosal integrity, showed only very transient increases in the Ontak-treated AGMs (n = 4, red), that superposed those of the inflammatory markers. Shown are the average fold increases from the baseline for each group and standard error of means. Time points of Ontak treatment initiation (–2, 32, and 53 dpi) are shown by red arrows.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts